Skip to main content
SpringerLink
Log in

The UK NICE has recommended ezetimibe as a cost effective option for the treatment of primary hypercholesterolaemia.

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Merck Sharp and Dohme Ltd, schering pl.Nice Issues Final Appraisal Determination on Ezetrol(R) (Ezetimibe) for the Treatment of Adults With Primary Hypercholesterolemia. Media Release: 17 Sep 2007. Available from: URL: http://www.merck.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The UK NICE has recommended ezetimibe as a cost effective option for the treatment of primary hypercholesterolaemia.. Pharmacoecon. Outcomes News 538, 3 (2007). https://doi.org/10.2165/00151234-200705380-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705380-00007

Keywords

Search

Navigation